<DOC>
	<DOCNO>NCT01583283</DOCNO>
	<brief_summary>The purpose study determine best dose ACY-1215 combination lenalidomide dexamethasone patient relapse relapsed/refractory multiple myeloma . Once determine , purpose study determine efficacy ACY-1215 combination lenalidomide dexamethasone patient relapse multiple myeloma 1-3 prior therapy lenalidomide-refractory .</brief_summary>
	<brief_title>Study ACY-1215 Combination With Lenalidomide , Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description>This phase 1 , single-arm , multicenter , open-label study patient relapse relapsed/refractory MM . The study employ sequential group dose-escalation design determine DLT MTD ACY-1215 combination lenalidomide dexamethasone , administer orally ( PO ) . The safety , tolerability , single- multiple-dose PK , pharmacodynamics , anti-tumor activity ACY 1215 combination lenalidomide dexamethasone also evaluate . Each cohort enroll 3 patient . Study drug dos escalate sequentially Safety Review Committee ( SRC ) review safety data collect C1 ( 28 day ) patient enrol current dose level well emerge data ongoing study ACY-1215 . If DLTs ( define Section 5.2.6 ) C1 concern base data ongoing study , study proceed dose escalation next cohort follow safety data review SRC . If 1 3 patient DLT , 3 additional patient enrol cohort ; none additional 3 patient experience DLT C1 , escalation may continue next cohort follow SRC review . If 2 patient DLTs C1 , DLT dose level reach . The MTD define dose level immediately DLT dose level . A total 6 additional patient may enrol MTD appropriate dose level obtain additional AE , PK , pharmacodynamic , anti-tumor activity data ACY 1215 combination lenalidomide dexamethasone .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Relapsed Relapsed/Refractory MM progressive disease ( PD ) accord IMWG . Received least 1 prior line therapy MM ( Phase 1 ) Secretory MM patient previously receive 13 prior line therapy ( Phase 2 ) . Able provide write consent Not candidate autologous stem cell transplant ( ASCT ) decline option . ≥18 year age Karnofsky Performance Status score ≥ 70 Adequate bone marrow reserve evidence ANC &gt; 1.0x10^9/L ; Platelet &gt; 50x10^9/L Creatinine Clearance ≥ 50 mL/min Adequate hepatic function evidence serum bilirubin value &lt; 2.0 mg/dL ; ALT and/or AST &lt; 3xULN . Corrected serum calcium ≤ ULN Recovered effect prior systemic therapy radiotherapy Multiple Myeloma Able take acetylsalicylic acid ( ASA ) ( 81 325 mg ) daily prophylactic anticoagulation . Patients intolerant ASA may use low molecular weight heparin . Lovenox recommend . Coumadin allow provide patient fully anticoagulated , INR 2 3 . Agreement participate RevAssist® Program Female childbearing potential must negative serum urinary pregnancy test sensitivity least 50 mIU/mL 1014 day prior within 24 hour prescribe lenalidomide Cycle 1 must either commit continued abstinence begin TWO acceptable method birth control , one highly effective method one additional effective method time , least 28 day prior take lenalidomide . Also agree ongoing pregnancy test . If male , include vasectomy , must agree use latex condom sexual contact female childbearing potential . Received follow antitumor therapy Radiotherapy systemic therapy within 2 week Cycle 1 Day 1 ( C1D1 ) Investigational biologic therapy within 3 week C1D1 Prior peripheral ASCT within 12 week C1D1 Prior allogeneic stem cell transplant Prior treatment histone deacetylase ( HDAC ) inhibitor Presence active systemic infection require treatment . History malignancy unless . ) patient undergone definitive treatment 5 year prior without evidence recurrent malignant disease b . ) basal squamous cell carcinoma skin ; superficial carcinoma bladder ; carcinoma prostate current prostat specific antigen &lt; 0.1 ng/mL ; ductal carcinoma situ ; cervical intraepithelial neoplasia . Known suspected human immunodeficiency virus ( HIV ) , hepatitis B surface antigenpositive status know suspect active hepatitis C infection . If female , lactate . History significant cardiovascular , neurological , endocrine , gastrointestinal , respiratory , inflammatory illness could preclude study participation , pose undue medical hazard , interfere interpretation study result , include limited congestive heart failure ( NYHA Class 3 4 ) , unstable angina ; cardiac arrhythmia , recent ( within past 6 month ) myocardial infarction stroke ; uncontrolled hypertension ; diabetes mellitus &gt; 2 episode ketoacidosis precede 12 month , COPD require &gt; 2 hospitalization precede 12 month QTcF &gt; 480 msec , family personal history long QTc syndrome ventricular bigeminy ; previous history druginduced QTc prolongation need medication know suspected produce prolonged QTc interval ECG Current enrollment another clinical trial involve treatment and/or receive investigational agent reason Documented plasma cell leukemia know amyloidosis . ( Plasma cell leukemia define presence &gt; 20 % plasma cell peripheral blood absolute plasma cell count ≥2000 muL Known hypersensitivity thalidomide lenalidomide . History erythema nodosum characterize desquamating rash take thalidomide similar drug . Nonsecretory oligosecretory Multiple Myeloma ( Phase II ; disease permissible Phase I ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>